UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patient

- The transaction, which was announced October 10, 2019, will enhance UCB's potential to be a leader in myasthenia gravis by adding zilucoplan, a peptide inhibitor ... Lees verder

Bron:

ANP Pers support